Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation (IMPRESS study)

Journal of the American College of Cardiology

Volumn 40, Issue 11, 2002, Pages 1935-1942

  Versaci, Francesco ^a   Gaspardone, Achille ^a   Tomai, Fabrizio ^a   Ribichini, Flavio ^b   Russo, Paolo ^c   Proietti, Igino ^a   Ghini, Anna Silvia ^a   Ferrero, Valeria ^b   Chiariello, Luigi ^a   Gioffrè, Pier Agostino ^e   Romeo, Francesco ^a   Crea, Filippo ^d  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c S CROCE E CARLE HOSPITAL   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e EUROPEAN HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; DELTACORTENE; PANTOPRAZOLE; PREDNISONE; TICLOPIDINE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ANTIINFLAMMATORY ACTIVITY; ARTERY DIAMETER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GLUCOSE INTOLERANCE; HEART INFARCTION; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RESTENOSIS; STOMACH PAIN; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; BLOOD VESSEL PROSTHESIS IMPLANTATION; C-REACTIVE PROTEIN; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL ISCHEMIA; PREDICTIVE VALUE OF TESTS; PREDNISONE; STENTS; TREATMENT OUTCOME;

EID: 0037021563     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)02562-7     Document Type: Article

References (32)

1. Lowe HC, Oesterle SN, Khachigian LV. Coronary in-stent restenosis: Current status and strategies. J Am Coll Cardiol 2002;39:183-93.
2. Serruys PW, De Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. BENESTENT Study Group. N Engl J Med 1994;331:489-95.
3. Fischman DL, Leon M, Baim DS, et al. A randomised comparison of coronary-stent implantation and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Group Investigators. N Engl J Med 1994;331:496-501.
4. Versaci F, Gaspardone A, Tomai F, et al. A comparison of coronary-artery stenting with angioplasty for isolated stenosis of the proximal left anterior descending coronary artery. N Engl J Med 1997;336:817-22.
5. Dussailant GR, Mintz GS, Pichard AD, et al. Small stent size and intimal hyperplasia contribute to restenosis: A volumetric intravascular ultrasound study. J Am Coll Cardiol 1995;26:720-4.
6. Hoffman R, Mintz GS, Dussailant GR, et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 1996;94:1247-54.
7. Mudra H, Regar E, Klauss V, et al. Serial follow-up after optimized ultrasound-guided deployment of Palmaz-Schatz stents. In-stent neointimal proliferation without significant reference segment response. Circulation 1997;95:363-70.
8. Shirotani M, Yui Y, Kawai C. Restenosis after coronary angioplasty: Pathogenesis of neointimal thickening initiated by endothelial loss. Endothelium 1993;1:5-22.
9. Forrester JS, Fishbein M, Helfant R, Fagin J. A paradigm for restenosis based on cell biology: Clues for the development of new preventive therapies. J Am Coll Cardiol 1991;17:758-69.
10. Pietersma A, Kofflard M, de Wit EA, et al. Late lumen loss after coronary angioplasty is associated with the activation status of circulating phagocytes before treatment. Circulation 1995;91:1320-5.
11. De Servi S, Mazzone A, Ricevuti G, et al. Granulocyte activation after coronary angioplasty in humans. Circulation 1990;82:140-6.
12. Kornowoski R, Hong MK, Tio FO, Bramwell O, Wu H, Leon MB. In-stent restenosis: Contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 1998;31:224-30.
13. Helle M, Boeije L, Pascaual-Salcedo D, Aarden L. Differential induction of interleukin-6 production by monocytes, endothelial cells and smooth muscle cells. Progr Clin Biol Res 1991;367:61-71.
14. Jang Y, Lincoff AM, Plow EF, Topol EJ. Cell adhesion molecules in coronary artery disease. J Am Coll Cardiol 1994;24:1591-601.
15. Ikeda U, Ikeda M, Oohara T, et al. Interleukin-6 stimulates growth of vascular smooth muscle cells in a PDGF-dependent manner. Am J Physiol 1991;250:1713-7.
16. 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U S A 1987;84:7251-5.
17. Gaspardone A, Crea F, Versaci F, et al. Predictive value of C-reactive protein after successful coronary artery stenting in patients with stable angina. Am J Cardiol 1998;82:515-8.
18. Walter DH, Fichtlscherer S, Sellwig M, Auch-Schwelk W, Schächinger V, Zeiher AM. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol 2001;37:839-46.
19. MacDonald RG, Panush RS, Pepine CJ. Rationale for use of glucocorticoids in modification of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1987;60:56B-60B.
20. Stone GW, Rutherford BD, McConahay DR, et al. A randomized trial of corticosteroids for the prevention of restenosis in 102 patients undergoing repeat coronary angioplasty. Cathet Cardiovasc Diagn 1989;18:227-31.
21. Pepine CJ, Hirshfeld JW, MacDonald RG, et al. A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty. Circulation 1990;81:1753-61.
22. Lee CW, Chae J, Lim H, et al. Prospective randomized trial of corticosteroids for the prevention of restenosis after intracoronary stent implantation. Am Heart J 1999;138:60-3.
23. Parbroth MG, Reitz BA. Heart and heart-lung transplantation. In Braunwald E, editor. Heart Disease. A Textbook of Cardiovascular Medicine. 5th Ed. Philadelphia, PA: W.B. Saunders, 1997:512-33.
24. Campeau L. Grading of angina pectoris. Circulation 1976;54:522-3.
25. Hamm C, Braunwald E. A classification of unstable angina revisited. Circulation 2000;102:118-22.
26. World Health Organization Principal Investigators (prepared by Tunstall-Pedoe H). The World Health Organization MONICA project (MONItoring trends and determinants in CArdiovascular disease): A major international collaboration. J Clin Epidemiol 1988;41:105-14.
27. Crea F, Gaspardone A, Tomai F, et al. Risk factors in schoolchildren associated with a family history of unheralded myocardial infarction or uncomplicated stable angina in male relatives. J Am Coll Cardiol 1994;23:1472-8.
28. Reiber JHC, van Land CD, Koning G, et al. Comparison of accuracy and precision of qualitative coronary arterial analysis between cinefilm and digital system. In: Reiber JHC, Serruys PW, editors. Progress in Quantitative Coronary Arteriography. Dordrecht, The Netherlands: Kluwer Academic Publishers, 1994:67-85.
29. Grewe PH, Deneke T, Machraoui A, Barmeyer J, Mueller KM. Acute and chronic tissue response to coronary stent implantation: Pathologic findings in human specimen. J Am Coll Cardiol 2000;35:157-63.
30. Buffon A, Liuzzo G, Biasucci LM, et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999;34:1512-21.
31. Versaci F, Gaspardone A, Tomai F, et al. Predictive value of C-reactive protein in patients with unstable angina pectoris undergoing, coronary artery stent implantation. Am J Cardiol 2000;85:92-5.
32. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80.